The short version of freeze-thaw cycle fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-12. Anything still debated is marked as such rather than presented as settled.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Founded in 2007 and located in Culpeper, Virginia in Northern Virginia, the National Audio-Visual Conservation Center is the Library of Congress's newest building. It was constructed out of a former Federal Reserve storage center and Cold War bunker. The campus is designed to act as a single site to store all of the library's movie, television, and sound collections. It is named in honor of David Woodley Packard, whose Packard Humanities Institute oversaw the design and construction of the facility. The centerpiece of the complex is a reproduction Art Deco movie theater that presents free movie screenings to the public on a semi-weekly basis.
Magnesium metal and its alloys can be explosive hazards; they are highly flammable in their pure form when molten or in powder or ribbon form. Burning or molten magnesium reacts violently with water. When working with powdered magnesium, safety glasses with eye protection and UV filters (such as welders use) are employed because burning magnesium produces ultraviolet light that can permanently damage the retina of a human eye. Magnesium is capable of reducing water and releasing highly flammable hydrogen gas:
== Academic integrity == SCIRP generated controversy in 2010 when it was found that its journals duplicated papers which had already been published elsewhere, without notification of or permission from the original author and of the copyright holder. Several of these publications have subsequently been retracted. Some of the journals had listed academics on their editorial boards without their permission or even knowledge, sometimes in fields very different from their own. In 2012, one of its journals, Advances in Pure Mathematics, accepted a paper written by a parody generator; the paper was not published, but only due to its author's unwillingness to pay the publication fee. The company has also been noted for the many unsolicited bulk emails it sends to academics about its journals. In 2013, the Open Journal of Pediatrics, a SCIRP journal, published a study which concluded that the number of babies born with thyroid problems in the western United States increased by 16 percent in 2011 compared to 2010, after the Fukushima Daiichi nuclear disaster. The study has been criticized for not taking into account the fact that 2010 was a year with an unusually low number of births with thyroid problems. SCIRP refused to print a letter criticizing the study, but offered to publish it as an article for a charge. The company has been included in a list of questionable open access publishers, according to Jeffrey Beall's criteria. Beall states that "This publisher exists for two reasons.
Sources: en.wikipedia.org
==== Type I antithrombin deficiency ==== Type I antithrombin deficiency is characterized by a decrease in both antithrombin activity and antithrombin concentration in the blood of affected individuals. Type I deficiency was originally further divided into two subgroups, Ia and Ib, based upon heparin affinity. The antithrombin of subgroup Ia individuals showed a normal affinity for heparin while the antithrombin of subgroup Ib individuals showed a reduced affinity for heparin. Subsequent functional analysis of a group of 1b cases found them not only to have reduced heparin affinity but multiple or 'pleiotropic' abnormalities affecting the reactive site, the heparin binding site and antithrombin blood concentration. In a revised system of classification adopted by the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, type Ib cases are now designated as type II PE, Pleiotropic effect. Most cases of type I deficiency are due to point mutations, deletions or minor insertions within the SERPINC1 gene. These genetic mutations result in type I deficiency through a variety of mechanisms:
==== Elimination ==== The elimination of etilefrine is dependent on route of administration. Regardless of route, about 80% is excreted in urine within 24 hours. With oral administration, 7% is eliminated unchanged in urine and 73% as conjugates. Conversely, with intravenous administration, 28% is eliminated unchanged in urine and 44% as conjugates.
Carbazole 1,9a-dioxygenase (EC 1.14.12.22, CARDO) is an enzyme with systematic name 9H-carbazole,NAD(P)H:oxygen oxidoreductase (2,3-hydroxylating). This enzyme catalyses the following chemical reaction
=== Immunology === Simponi (golimumab) ($0.5 billion in 2024 revenues) is an immunosuppressive drug. Remicade (infliximab) ($0.1 billion in 2024 revenues) is a monoclonal antibody directed toward the cytokine TNF-alpha and used for the treatment of a wide range of autoimmune disorders, including rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, plaque psoriasis, and others. Remicade and other TNF-alpha inhibitors exhibit additive therapeutic effects with methotrexate and improve quality of life. Adverse effects include increased risk of infection and certain cancers. Merck had rights to the drug in certain areas, while Janssen Biotech had rights in other areas; in 2017, Merck announced a biosimilar to Remicade, Renflexis.
Sources: en.wikipedia.org
On August 8, 2019, the Ford government severed the funding for court-ordered autism services for eight families with adult children with "severe" conditions who are at "serious risk of harm", who had been receiving the funding since 2004. Lawyers Scott Hutchison and Mary Eberts served notice of intent to sue in an 18-page letter to Social Services Minister Smith and Premier Ford "for breach of contract, negligence, and breach of Charter rights." It was formally filed in court on October 1. Those long-standing payments of about $1.7 million annually were the result of litigation against the previous provincial administrations, who had committed to continue the funding "until a co-ordinated transition to other services had been made, in a way that provided alternative services with which the families were satisfied", according to The Star. Faced with a backlash against "a botched revamp of autism services" in February 2019, the government had doubled the annual funding to $600 million for autism services but this did not restore the funding for these eight families.
==== Neurodegeneration ==== Research has been conducted on the effects of stem cells on animal models of brain degeneration, such as in Parkinson's disease, Amyotrophic lateral sclerosis, and Alzheimer's disease. Preliminary studies related to multiple sclerosis have been conducted, and a 2020 phase 2 trial found significantly improved outcomes for mesenchymal stem cell treated patients compared to those receiving a sham treatment. In January 2021 the FDA approved the first clinical trial for an investigational stem cell therapy to restore lost brain cells in people with advanced Parkinson's disease. Healthy adult brains contain neural stem cells, which divide to maintain general stem-cell numbers, or become progenitor cells. In healthy adult laboratory animals, progenitor cells migrate within the brain and function primarily to maintain neuron populations for olfaction (the sense of smell). Pharmacological activation of endogenous neural stem cells has been reported to induce neuroprotection and behavioral recovery in adult rat models of neurological disorders.
The Children's Story (1982) short film, which originally aired on TV's Mobil Showcase, depicts the first day of indoctrination of an elementary school classroom by a new teacher, representing a totalitarian government that has taken over the United States. It is based on the 1960 short story of the same name by James Clavell. The Day After (1983) – This made-for-television-movie by ABC that depicts the consequences of a nuclear war in Lawrence, Kansas and the surrounding area. WarGames (1983) – About a young computer hacker who unknowingly hacks into a defense computer and risks starting a nuclear war. Testament (PBS, 1983) – Depicts the after-effects of a nuclear war in a small town, 100 miles north of San Francisco, California. Countdown to Looking Glass (HBO, 1984) – A film that presents a simulated news broadcast about a nuclear war. Threads (BBC, 1984) – A film that is set in the British city of Sheffield and shows the long-term results of a nuclear war on the surrounding area. The Sacrifice (Sweden, 1986) – A philosophical drama about nuclear war. The Manhattan Project (1986) – Though not about a nuclear war, it was seen as a cautionary tale. When the Wind Blows (1986) – An animated film about an elderly British couple in a post-nuclear war world. Miracle Mile (1988) – A film about two lovers in Los Angeles leading up to a nuclear war. By Dawn's Early Light (HBO, 1990) – About rogue Soviet military officials framing NATO for a nuclear attack in order to spark a full-blown nuclear war. On the Beach (Showtime, 2000) – A remake of the 1959 film.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.